






Strategic Shifts for GC8: NextGen Market Shaping

54th Board Meeting

GF/B54/08

12–13 February 2026, Geneva, Switzerland

For Input



Executive Summary [1/3]

Context

1. The NextGen Market Shaping approach was introduced in 2022 to improve access to quality assured and affordable health products and innovations. Significant progress has been made on all strategic priorities: [i] catalyzing and accelerating access to innovation; [ii] building regional capacity for manufacturing and collaborative procurement; and [iii] strengthening in-country supply chains. This also includes the update and operationalisation of the Global Fund's Quality Assurance Policies and Procurement Policy.
2. Progress and achievements to date have enabled us to respond effectively to the evolving context. The Secretariat recognizes the need to accelerate and evolve its market shaping approach to sustain the investment outcomes and support countries transitioning in GC8 and beyond.
3. The Board is receiving this update now as part of discussions on strategic shifts for GC8.

Questions addressed in this slide deck

- A. How should the NextGen Market Shaping approach evolve to respond to the current context to deliver further impact, building on the progress made?
- B. How can we support sustainability and the transition agenda through procurement collaboration, including scaling up of non-grant financed procurement via PPM/wambo.org?
- C. What is needed to ensure success going forward?

Executive Summary [2/3]

Conclusions

Key NextGen Market Shaping achievements include:

1. Shaping markets to deliver affordable, sustainable access to innovations, including dual active ingredient insecticide treated nets (dual active ingredient ITNs) through use of the Revolving Facility and breakthrough interventions to enable early scaled introduction of lenacapavir for PrEP as of day one, supported by the Access Fund.
2. Regional manufacturing capacity has been enhanced through collaboration with partners on supportive activities. Increased number of eligible Africa manufacturers and procurement of Insecticide treated nets (ITNs), antimalarial medicines (ATMs) and antiretroviral medicines (ARVs).
3. Regional procurement partnerships with Africa CDC and several Regional Economic Communities have been enhanced with strategic considerations to leverage the PPM / wambo.org platform.
4. Country driven and partner supported transformations have resulted in more cost-efficient and effective supply chains through digitization and integrated approaches.
5. An additional US\$25m in private sector Access Funding has been catalyzed through the NextGen Market Shaping Catalytic Investment (CI) as of September 2025 over the previous Board-approved amount for GC7, with additional aligned contributions of US\$10.5m from the Gates Foundation and pipeline pledges of an additional US\$34.4m from CIFF.

Executive Summary [3/3]

Conclusions [continued]

- A. The proposed evolution of the Global Fund's market shaping approach builds on progress made and includes key strategic shifts to better respond to the evolving context:
 - 1. Maintain strategic pillar for Innovation and New Product Introduction.
 - 2. Expand regional capacity building intervention to focus on procurement collaboration, while maintaining manufacturing capacity building efforts through harmonized quality assurance standards and partnerships.
 - 3. Focus on sustaining healthy markets and supporting end-to-end supply chain integration, efficient delivery models and access.
 - 4. Elevate non-grant financed Procurement Mechanism as an emerging strategic lever.
- B. To sustain the progress and support countries transitioning from Global Fund support, the Secretariat intends to accelerate and scale up the non-grant procurement mechanism. This will require updated policies, including the development of a pre-financing mechanism and fostering strategic procurement partnerships.
- C. To progress, we will maximize impact through the NextGen Market Shaping Catalytic Investments and aim to mobilize additional resources to accelerate and scale up prioritized interventions.

Input Received: Committees/Board discussions on Grant Cycle 8 CIs and the Informal Board Call on Lenacapavir.


Input Sought:

- 1. Does the updated NextGen Market Shaping approach appropriately respond to the evolving context, maximizing outcomes in GC8 and supporting country transitions, including the proposed acceleration and scaling up of the non-grant financed procurement mechanism as well as the development of a pre-financing facility?
- 2. Are the next steps, including Committee / Board engagement, appropriate and on the right timeline?

Contents

- 1 NextGen Market Shaping – Results in GC7**
- 2 Evolving NextGen Market Shaping for sustainable impact in GC8, supporting country transition**
- 3 Spotlight: Accelerate and scale up the non-grant financed procurement mechanism**
- 4 What is needed to ensure success**

GC7 NextGen Market Shaping and Key Progress



OVERVIEW OF KEY PROGRESS



- 1** Leveraged our market shaping tools, including the Global Fund's Quality Assurance Policies, the Global Fund's Procurement Policy, the Revolving Facility, the Access Fund and the Global Fund's Pooled Procurement Mechanism to:
 - a** Continue the rapid transition to dual active ingredient nets to address insecticide resistance;
 - b** Introduce Lenacapavir for PrEP simultaneously with upper income countries; and
 - c** Support the diversification of multiple first line therapies for malaria to address drug resistance threat.
- 2** Promoted capacity building of regional manufacturing and procurement through regulatory harmonization efforts and engagement with Africa CDC and Regional Economic Communities for increased self-reliance.
- 3** Drove supply chain efficiencies through digitalization of information systems and optimization of inventory levels and distribution networks in several African countries.

See Annex 1 for additional information.

Because of this progress, we are in a better position to rapidly respond to the evolving context. The NextGen Market Shaping Framework can be further leveraged to address strategic shifts for GC8.

GC7 NextGen Market Shaping Investment

The NextGen Market Shaping Catalytic Investment (CI) has created a platform that successfully leveraged additional private sector investments in GC7 to advance key priorities.



Contents

- 1 NextGen Market Shaping – Results in GC7
- 2 Evolving NextGen Market Shaping for sustainable impact in GC8, supporting country transition**
- 3 Spotlight: Accelerate and scale up the non-grant financed procurement mechanism
- 4 What is needed to ensure success

NextGen Market Shaping approach must evolve to sustain progress, respond to the evolving context and support country transition pathways

KEY CHALLENGES

1. Evolving public health landscape resulting in significant ecosystem shifts
2. Geopolitical crises and trade/tariffs causing market and access disruptions
3. Constrained and reduced funding

While the challenges may be great, we do have important levers that can help overcome them

KEY OPPORTUNITIES


1. Impressive pipeline of innovative, more efficacious health products for all three diseases that need to get to market quickly
2. Global Fund's highly efficient and effective pooled procurement mechanism and unique market shaping position
3. Global Fund's country model and partnerships to ensure outcomes and impact

GC8 - Evolving the Global Fund's market shaping approach to sustain progress, accelerate impact and support transition

STRATEGIC PRIORITIES

Meeting the challenges of the moment will require evolving our market shaping approach to accelerate impact:

- 1 Maintain focus on innovation at scaled impact through effective use of the Access Fund and the Revolving Facility, ensuring innovative and new products can be introduced early and at scale.
- 2 Increase focus on collaboration for procurement, including regional pooled procurement, leveraging Global Fund's core strength. Continue partnership efforts to promote a regionally diversified manufacturing and supply base.
- 3 Focus on sustainability, ensure healthy markets and drive efficient and integrated, resilient supply chains explore multi-channel approaches and last mile efficiency.
- 4 Accelerate the scale-up of the non-grant financed procurement through PPM/wambo.org to support sustainable and efficient access to live saving health products and countries transitioning from GF financing.




The evolved NGMS framework remains within the scope of the Board-approved GC8 NGMS priority.

NextGen Market Shaping will continue to drive equitable access to affordable and quality assured health products and innovations with GC8 strategic shifts

Use case:
NextGen Market Shaping will continue to drive improved access to affordable, quality assured health products and innovations that are more efficient and effective for responding to HTM disease burdens

1
Shape **innovation and accelerate health product introductions at scale**



2 Promote **regional capacity building for procurement and manufacturing**

3 Sustain **healthy markets and drive sustainable, efficient, resilient supply chains**

4 Accelerate **scale-up of non-grant financed procurement**

Use case:
Key interventions, such as digitalization of supply chains, would be adapted to the different country cohorts, leveraging grant and domestic financing catalyzed through the NGMS Strategic Initiative

Use case:
Countries preparing for transition can continue to access low-cost, high quality health products and innovations via PPM/wambo.org with domestic resources through the non-grant financed procurement mechanism

Notes: The approach taken, especially for countries around the margins of the groupings, will need to account for factors such as epidemic stage (increasing vs stable/declining), enabling rights environment, political will, fiscal capacity etc. Allocation bubbles represent size of GC7 allocation (pre-2025 funding reprioritization). Income thresholds are using 2024 data and thresholds, Disease burden is composite burden measure as used in GC7 allocation. * Placing on graphic does not necessarily represent income level and disease burden of COE country.


1: Shape innovation and accelerate health product introduction at scale including through multiple channels [1/5]

November 2025

VISION

Newer, better health product innovations are introduced rapidly and at scale for impact, using Global Fund’s comparative advantages and key tools, including the Revolving Facility and Access Fund.

There is a rich and promising product pipeline across the three diseases and across grant cycles that has been mapped with partners to inform market shaping interventions.



- = Prevention tool
- = Diagnostic tool
- = Therapeutic tool
- = Mix of prevention, diagnostic and/or therapeutic tools
- = Screening tool
- - - - = Dashed line indicates more limited potential of coming to market
- ★ = Proposed initial use cases
- = Active
- ➔ = Unitaid grants / Global Fund collaboration

Illustrative, not exhaustive. Reflects work with many other partners not shown here.

Future plans subject to availability of funds

*variety of biomarkers and technology platforms, including lateral flow test platforms; novel biomarkers; hemozoin detection, and volatile biomarker signatures and technologies

AHD = Advanced HIV disease

Dual-AI = Dual active ingredient




COIM = Co-infections and co-morbidities

EVT = Elimination of vertical transmission

POC = Point of care


1: Shape innovation and accelerate health product introduction at scale including through multiple channels [2/5]

GC8 Market Shaping will aim to catalyze access to innovation and take a holistic approach to ensuring sustainable, affordable markets, with a balanced portfolio across HIV, TB, and Malaria — from prevention to diagnosis to treatment.

SELECT PRODUCTS	SUMMARY OBJECTIVES / APPROACH
 <p>Lenacapavir for pre-exposure prophylaxis (LEN for PrEP)</p> <p>HIV Rapid Diagnostic Tests (RDTs) – Prof. + Multiplex</p> <p>HIV RDTs – Self tests</p>	<p>Dramatically reduce new HIV infections by catalyzing and shaping the market for Lenacapavir, scaling the market as soon as available from the originator, enabling accelerated generic development and affordable, sustainable pricing. Support domestic HIV program sustainability through reduced new HIV infections over time; create the market for sustainable generics and ensure their accessibility through all appropriate channels.</p> <p>Achieve material savings via increased share of already available, lower-priced products via demand shaping work in select high-volume countries.</p> <p>Shift country-based decisions on product selection towards less expensive tests primarily through existing levers, limiting preference bias, and light demand-side work.</p>
 <p>Dual AI & Next-Gen ITNs</p> <p>Novel Vector Control (Spatial emanators)</p> <p>Novel ACTs: Ganaplacide - Lumefantrine & Triple ACTs</p> <p>ASPY + DP (including generics)</p> <p>Malaria RDTs</p>	<p>Continued diversification of active ingredient at prices comparable with other Dual Active Ingredient (AI) nets, while also facilitating expansion of regional manufacturing.</p> <p>Supporting uptake and market viability of this novel intervention aligned with conditional WHO recommendation for supplementary use alongside insecticide-treated nets (ITNs) - through initial roll out / pilots in key use cases for operational evidence building.</p> <p>Secure near-Artemether-lumefantrine (AL) pricing via volume guarantees and Access Fund, as needed, new formulations will be important additions to multiple first line therapies (MFTs) to protect Lumefantrine and partner drugs.</p> <p>Strengthen current MFT toolkit options with a focus on solving for 2026 transition year until less expensive generics become available in 2027, including in-country rollout across all appropriate public and private channels.</p> <p>Rely on a healthy product pipeline but provide time-limited support through the Access Fund to bridge modest residual premium that will remain after partner bilateral volume guarantees (Gates/MedAccess) and increase rate of use of Malaria RDTs in private sector channels through market-shaping efforts.</p>
 <p>Near Point of Care (NPOC) TB Diagnostics</p>	<p>Rapid scale-up of new technology across all relevant channels to enable meeting WHO-recommended diagnostic test coverage targets at a significant price discount to current alternatives, while ensuring a sustainable market and competition.</p>

1: HIV Innovation Pipeline & Prioritized Interventions [3/5]

HIV & COIM*



Product	Objective	Market Shaping Levers
Lenacapavir for pre-exposure prophylaxis (LEN for PrEP)	Dramatically reduce new HIV infections with introduction at scale of highly-effective long-lasting HIV prevention method; support domestic HIV program sustainability through reduced new HIV infections over time; create the market for sustainable generics.	<ul style="list-style-type: none"> Access Fund will be leveraged to support initial product introduction, until sustainable pricing has been achieved through generics entry. Partner Collaboration on demand generation and country readiness support, including complying to pharmacovigilance and market surveillance requirements. Revolving Facility can be leverage to accelerate timings for LEN PrEP generics and secure supply capacity. Sustainability & Exit need to be planned as part GC8 once the sustainable pricing and supply has been reached .
HIV Rapid Diagnostic Tests (RDTs) – Prof. + Multiplex	Achieve material savings via increased share of already available, lower-priced products via demand shaping work in select high-volume countries.	<ul style="list-style-type: none"> WHO Guidance Advocacy: Stimulate adoption of WHO recommendations. Country Readiness Technical Assistance: Support for verification studies for multiple products. Africa-based manufacturing: Where economically efficient, encourage adoption of regionally-manufactured RDTs. Sustainability & Exit: Expand interchangeability of HIV RDTs to drive reasonable cost reduction and increased supply security.
HIV RDTs – Self	Shift country-based decisions on product selection towards less expensive test through existing levers, limiting preference bias, and light demand-side work.	<ul style="list-style-type: none"> Demand Side Adaptations: Stimulate adoption of WHO recommendations. Match Fund will be provided through CIFF supported by a Matching Fund in GC8, while leveraging partner efforts to create more competition vs. oral test.

 = Prevention tool
 = Therapeutic tool
 = Diagnostic tool

○ = Active Global Fund collaboration

✈ = Unitaid grants / Global Fund collaboration

 = Mix of prevention, diagnostic and/or therapeutic tools

AHD = advanced HIV disease

CIFF = Children's Investment Fund Foundation

COIM = co-infections and co-morbidities

DAA = direct-acting antiviral

HCV = hepatitis C virus


HRDT = HIV RDT

mRDT = malaria RDT

STI = sexually transmitted infection

TPT = TB preventive treatment

1: TB Innovation Pipeline & Prioritized Interventions [4/5]



Product	Objective	Market Shaping Levers
Near Point of Care (NPOC) TB Diagnostics	Rapid scale-up of new technology across all relevant channels to enable meeting WHO recommended diagnostic coverage targets at a significant price discount to current alternatives, while ensuring sustainable market and competition.	<ul style="list-style-type: none"> • Revolving Facility: Potential Volume guarantees for new NPOC manufacturers to secure lower entry prices and grow the market. • Access Fund: Potential co-payment support for countries for introduction and scale up, through US\$14.4m in GC7 from ClIFF, with potential further investment into GC8 • Demand Shaping: Technical Assistance pool and early purchasing procurement quantities for early adopters. • Sustainability & Exit: Target entry of multiple technologies and price competition (esp. compared to current status quo single-supplier dominant context) by end of GC8.

 = Prevention tool
 = Diagnostic tool
 = Therapeutic tool
 ● Active Unitaids grants / Global Fund collaboration
 = Screening tool
 = Mix of prevention, diagnostic and/or therapeutic tools

1: Malaria Innovation Pipeline & Prioritized Interventions [5/5]

2024-2026

2027-2029 (est. timing tbc)

2030-2032 (est. timing tbc)

Malaria



AS-PY/ DHA-PPQ for ACT diversification

Tenebenal based ITN - 1

Ganaplacide-Lumefantrine & Triple ACTs

Antimalarials with novel molecules

Non-invasive diagnostics*

Non-HRP2/3 RDTs

Genetically modified mosquito systems

Monoclonal antibodies

Spatial repellents / emanators

Transmission blocking/combo vaccine

CFP-only ITNs

Tenebenal ITNs- 2

Other novel ITNs

Endectocides

ATSB, eaves tubes

Product	Objective	Market Shaping Levers
Dual AI & Next-Gen Insecticide-treated nets (ITNs)	Continued diversification of active ingredient at prices comparable with other Dual AI nets, while also facilitating expansion of regional manufacturing.	<ul style="list-style-type: none"> • Revolving Facility (RF): Similar to GC7 transactions to secure scale-up of nets with new ingredient. • Access Fund (potential): As alternative to RF transaction, could pursue with Access Fund. • Demand Support: Support countries to adapt to multiple Dual Active Ingredients (AI) portfolio approach. • Sustainability & Exit: Target multiple ingredients to delay resistance and ensure affordable pricing which is comparable to Chlorfenapyr Dual AI. Regionally-manufactured nets.
Novel Vector Control (Spatial emanators)	Support uptake and market viability of this novel intervention aligned with conditional WHO recommendation for supplementary use alongside ITNs - through initial roll out / pilots in key use cases for operational evidence building	<ul style="list-style-type: none"> • Early Adopter Pilots: Pilots in a few countries for early adopter. • Implementation Research: Generate cost effectiveness data in use cases and evaluate deployment approaches. • Sustainability & Exit: Interventions are targeted specifically on maintaining the continued viability of the market for a product.
ASPY + DP (incl. generics)	Strengthen current Multiple First Line Therapies (MFT) toolkit until less expensive generics become available in 2027, including in-country rollout across all appropriate public and private channels.	<ul style="list-style-type: none"> • Access Fund: Support scale-up in additional countries. • Tactical Pooled Procurement: Continued negotiation with suppliers on terms. • Revolving Facility: Only if needed to assure supplier scale-up, potentially with securing API. • Demand Shaping: Technical support to scale-up to an additional countries. • Sustainability & Exit: Scale-up of additional countries supports scale. Requires introduction of generics in 2027 (ASPY) to exit the Access Fund + negotiated terms on dihydroartemisinin/piperaquine (DP).
Novel ACTs - Ganaplacide-Lumefantrine & Triple ACTs	Secure near-Artemether/lumefantrine (AL) pricing via Volume Guarantees and Access Fund, as needed, important additions to MFT to protect Lumefantrine and partner drugs	<ul style="list-style-type: none"> • Revolving Facility: Support originator + generics for capacity scale-up to have low launch price. • Access Fund: Reducing the price gap to AL and bridge to generics market entry. • Sustainability & Exit: Target generics entry by 2029, after 2-year financing intervention.

 = Prevention tool
 = Diagnostic tool
 = Therapeutic tool
 ● Active Unaided grants / Global Fund collaboration
 = Screening tool
 - - - - = Dashed line indicates more limited potential of coming to market

2: Promote regional capacity building for manufacturing and collaborative procurement [1/3]

VISION

Network of reliable suppliers producing quality-assured health products closer to the populations that need them, connected through global, regional, and national procurement, enabling more sustainable and responsive supply chains for equitable access to HTM health products, supporting self-reliance and country transitions

PROBLEMS WE ARE TRYING TO SOLVE

- 1 Fragmented supply chains, with inefficiencies, high costs, long lead times and limited bargaining power.
- 2 Very few regional manufacturing capacity meeting international quality standards, with heavy reliance on imports and vulnerability to global disruptions.
- 3 Diverse standards, procurement rules and quality regulations across countries that hinder cross-border collaboration.
- 4 Limited visibility into regional demand, production capacity and supplier performance, with missed opportunities for better planning and economies of scale.

WHAT WE SEEK TO ACHIEVE

- 1 Increased regional manufacturing capacity and regulatory harmonization through partnerships on technical assistance, leveraging the Expert Review Panel and joint assessments.
- 2 Strengthened regional pooled procurement platforms for predictable demand and sustained investment in regional manufacturing for self-reliance.
- 3 Collaborative procurement to retain scale, consolidate fragmented demand and stabilize pricing over time for strengthened market health and sustainability, especially important as countries transition towards greater domestic financing.

2: Continued Partnership on Regional Manufacturing [2/3]

JOINT PARTNERSHIP EFFORTS

- 1 Global Fund will continue working through partners (e.g., WHO, USP) to support regional regulatory harmonization and reliance, including to the newly established **African Medicines Agency**.
- 2 Several partners recently launched / are planning to launch new regional institutional capacity building initiatives for example:
 - **World Bank:** New 2025-2028 MOU includes collaboration on Procurement, Supply Chain, and Regional manufacturing capacity building.
 - **GIZ/BACKUP Health:** Collaborate on GC8 set-aside workstream for regional production technical assistance.
- 3 Global Fund will engage with partners, leveraging respective comparative strengths and complementary efforts across the ecosystem.

GLOBAL FUND EFFORTS

- 1 Continue to promote south-to-south collaboration to expand the supply base in Africa with manufacturers meeting Global Fund's quality assurance standards to improve supply security and sustainability.
- 2 Actively work with and support regional manufacturers to better understand Global Fund procurement cycles and requirements.
- 3 Continue to reflect the importance of a regionally diversified supply base in sourcing strategies and subsequent tenders.
 - This means using tender evaluation criteria that actively encourages regional manufacturing by recognizing suppliers with production sites closer to demand and those performing partial or full upstream production processes, warehousing and distribution within the region.
 - This approach shortens supply chains, reduces delivery times and strengthens supply reliability.

2: Accelerate Regional Procurement Collaborations [3/3]

Leveraging the Global Fund's Pooled Procurement Mechanism to continue to advance on collaborative procurement from joint demand and supply planning, harmonized quality standards, information exchange and market engagement

PAHO

- 1 Preferred partner for the Americas in the context of transition and sustainability (including through accessing PPM terms).
- 2 Continued procurement collaboration with the Global Fund for market shaping outcomes and lowest sustainable pricing.
- 3 Champion the collaborative procurement experience with PAHO as the ambition for other regional platforms.

REGIONAL ECONOMIC COMMUNITIES IN AFRICA

- 1 Support the foundation for long-term procurement capacity for strategies **implemented at the REC level**
- 2 In parallel, **optimize outcomes from collaborative procurement** including by leveraging PPM, as a practical pathway toward more integrated and sustainable procurement models across national, sub-regional, regional and global levels.

AFRICAN UNION / A-CDC

- 1 Support the foundation for long-term procurement capacity through strategies **implemented at the continental level**
- 2 In parallel, **optimize outcomes from collaborative procurement** including by leveraging PPM, as a practical pathway toward more integrated and sustainable procurement models across national, sub-regional, regional and global levels.

Contributing to the emergence of self-reliant, interoperable procurement ecosystems embedded within a coordinated global–regional–national architecture for stable markets that support reliable access to quality-assured, affordable health products sustainably.

3: Sustain healthy markets and drive resilient and efficient supply chains [1/3]

VISION

Sustaining health markets means maintaining sufficient suppliers, capacity and sustainable pricing and access.

Digitally enabled in-country supply chains perform efficiently and effectively to ensure reliable access to quality-assured health products through all relevant channels.

This is achieved through supply chain visibility that enables informed decision-making, sustainable financing models and approaches that ensure last-mile reach.

PROBLEMS WE ARE TRYING TO SOLVE

- 1 Current context and transition risks market fragmentation and potential market failure, leading to price volatility and access gaps.
- 2 Health product markets are divided across public and private sectors and demand signals are incomplete, resulting in disjointed supply chains.
- 3 Planning and service design often place disproportionate weight on public-sector data and pathways, obscuring how people seek care and where access constraints arise.
- 4 Downstream logistics services may be inefficient, poor-performing, or may not exist in many places where they are needed.
- 5 In a tight fiscal environment, it is as yet unclear how funding streams (including government, donor, insurance, and others) should come together to enable the widest possible access to essential health products.

WHAT WE SEEK TO ACHIEVE

- 1 Sustain healthy markets through enhanced monitoring and remedial actions where needed for critical products.
- 2 Promote digital innovations for integrated demand planning and traceability.
- 3 Explore multi-channels approach and integrated delivery models.
- 4 Shape the supply chain services market for improved last mile delivery.
- 5 Develop sustainable supply chain financing models and approaches.

3: Sustain healthy markets and drive resilient and efficient supply chains [2/3]

Four key areas of work will drive catalytic innovations that accelerate supply chain efficiency and sustainability to promote equitable access to quality assured health products across all channels

WHAT

1

Maintain healthy, sustainable markets

2

Develop alternative channels and integrated delivery models including last mile

3

Promote digital innovations for integrated demand planning and traceability

4

Develop sustainable supply chain financing models and approaches

HOW

Market monitoring and action to ensure sustainability and avert market failure

Leverage Global Fund's market visibility to assess market health, identify challenges and early warning indicators, and implement remedial action where needed, including leveraging NextGen Market Shaping tools as appropriate.

Efficient people-centered service delivery models, exploring multi-channel approaches, shaping downstream logistics provider markets

Expand access beyond traditional service delivery points, leveraging private sector capabilities, catalyzing greater options for performance-based, reduced cost of service for logistics services contracting.

Scaling digital innovations, including AI use cases and product traceability

Improve forecast accuracy, data visibility, traceability and verification of products, optimize the use of data for performance management for more efficient and integrated supply chain operations, minimizing wastage and ensuring supply chain integrity.

Sustainable financing models for supply chains

To support countries to develop sustainable supply chain financial and business models, including through alternative funding sources, with full visibility of operational costs and how best to sustain them.

3: Advancing partnership collaboration to accelerate supply chain transformations [3/3]

JOINT PARTNERSHIP EFFORTS

Along with Gates Foundation, Gavi, GFF and World Bank, convene an annual gathering senior health supply chain leaders from over 25 countries across Africa and Asia to tackle critical challenges in global health supply chains and advancing sustainable transformation through:

- 1 Planning** | Transforming strategic visions into actionable national plans for sustainable health supply networks.
- 2 Prioritization** | Identifying high-impact, evidence-driven innovative solutions to shape transformation priorities.
- 3 Partner** | Strengthening collaboration and expertise to accelerate in-country transformations.

AFRICA CDC

The Global Fund and Africa CDC will leverage current and future funding streams to:

- 1** Strengthen regional supply chain coordination and governance mechanisms.
- 2** Advocate for enhanced supply chain financing and domestic resource mobilization.
- 3** Improve visibility, efficiency, and interoperability of supply chain data systems.
- 4** Institutionalize learning and innovation across African supply chain networks.

ACAME

- 1** The Global Fund is collaborating with ACAME to roll out the Global Health Maturity Model.
- 2** ACAME's regional network of 22 countries helps ensure consistent application of the methodology, ownership, peer learning, and a shared pathway toward higher maturity and long-term system excellence and sustainability.

4: Accelerate and scale up the non-grant financed procurement mechanism to sustain access [1/2]

As countries need to transition towards domestically funded health responses, the Global Fund intends to scale up its non-grant financed procurement mechanism to support access to quality health products at low cost. Key challenges need to be addressed, including the development of a pre-financing solution that is fit for purpose and fit for use.

VISION

Enable greater access to life-saving health commodities across procurers by leveraging Global Fund's PPM/wambo.org as part of the sustainability pathway and in support of country transitions

PROBLEMS WE ARE TRYING TO SOLVE


- 1 **Fragmented / low scale procurement:** Many small buyers negotiating individually with manufacturers means higher product costs, and in some cases delayed/no access to essential medicines
- 2 **Low cost-efficiency of domestic procurement:** Current domestically financed health product procurement often experiences higher product prices and much higher transaction costs
- 3 **Variable quality products:** Application of different quality standards may translate to substandard products and compromised program delivery outcomes
- 4 **Delayed and/or unequal access to innovations:** New innovations often take much longer for individual countries to access without a large, central concerted effort

WHAT WE SEEK TO ACHIEVE

- 1 **Sustainability/Transition:** More diversified sources of financing for health commodities that sustain scale and facilitate greater national program responsibility
- 2 **Availability and Affordability:** Continually lower costs while preserving global supply security for essential health products
- 3 **Quality:** Increasing usage of quality-assured products in country programs with internationally harmonized standards
- 4 **Innovation:** More rapid adoption of new, game-changing biomedical products through improved market shaping / coordination across buyers

4: Accelerating the non-Grant financed procurement mechanism as part of the sustainability and transition pathway [2/2]

Global Fund's Procurement Policy enables different approaches for collaborative procurement with partners/buyers suited to the needs. These differentiated models can help maximum scale synergies and drive cost efficient and transparent procurement at national, regional and global levels



Contents

- 1 NextGen Market Shaping – Results in GC7
- 2 Evolving NextGen Market Shaping for sustainable impact in GC8, supporting country transition
- 3 Spotlight: Accelerate and scale up the non-grant financed procurement mechanism**
- 4 What is needed to ensure success

Key elements under consideration for the Non-Grant Financed Procurement Strategy and Policy Update

Strategy

Provide an efficient and sustainable procurement channel for countries to respond to downward pressure on supply chain costs and enable program cost efficiency, supporting country transitions. NGFP could also serve as a reference model to drive transparency and benchmarking as countries and regions enhance their pooled procurement mechanisms.

Operating Model

Develop differentiated and hybrid operating model to facilitate the use of NGFP mechanism

Product Scope

Eligible product scope available in wambo.org, including HTM core and specialized products, innovation, selected NCDs (COIM policy), RSSH and AMR

Buyer / User Eligibility

Need to review and enhance the scope of eligibility criteria for definition of payer or financier, buyer and user of wambo.org

Procurement Pre-Financing

Develop an adequate and effective pre-financing solution to support and incentivize countries to use NGFP

In addition, due considerations to be made on:

- 1 Procurement Negotiations and Long-term Agreements
- 2 Cost per service model
- 3 Partner collaboration
- 4 Operationalization, monitoring and reporting
- 5 Financial, Risk and Oversight Management

There are several key challenges / considerations to address to enable the scale-up of non-grant financed procurement

National procurement laws

Country procurement laws and regulations may not allow or limit the use of PPM/wambo.org

Pre-payment requirement

Countries not willing/able to pay upfront prior to receiving goods (pre-payment)

Differential procurement priorities

Countries may have particular objectives not accounted for in PPM/wambo.org offerings, such as sourcing from local manufacturers, different QA/regulatory standards and definition of best value

Shorter lead times

Countries may need faster than standard lead time for orders, especially “emergency” orders

Substitute for national capacity building

Countries may prefer to focus on capacitating and utilizing their own national procurement system instead of leveraging PPM/wambo.org even if total cost is higher

Lack of buyer eligibility

Private sector entities and certain large-scale pooled procurers may not be eligible to use platform as of today

Limited product catalogues

Domestically financed procurement often target health products beyond PPM/wambo.org catalogues

NGFP Lever: a pre-financing facility to meet the pre-payment requirement is under development

A viable pre-financing solution would remove or address a barrier for some countries to comply with the pre-payment requirement. It also may incentivize more country buyers to utilize PPM/wambo.org. The design must consider and mitigate potential risks.

Why is a pre-financing facility needed

PPM/wambo.org requires **pre-payment** to proceed with procurement transactions. When a Buyer cannot perform the pre-payment, a pre-financing facility is needed to:

- A. De-risk financial liability** incurred at the time when a purchase order is placed at the suppliers.
- B. Actuate payment to manufacturers** at the time when products are shipped to the countries.

What is a pre-financing facility

A pre-financing facility serves as a mechanism to manage financial requirements for specific procurement transactions. There are different ways to set up a pre-financing facility. Typically, the facility includes:


- A defined amount of cash or credits that will enable a procurement transaction to proceed.
- Adequate collateral modalities such as a letter of credit.
- Defined rules and regulation for the use of the facility.
- Defined governance, monitoring and reporting requirements.

Key risks to be considered

There are different risks to be considered, including:

- **Scale** of the facility needs to correspond to the scale of the non-grant financed procurement transactions.
- Modalities for **collaterals** used to cover initial payments to place orders.
- **Governance model** and shareholders' role for the facility.
- **Cost / benefits** and level of effort to operationalize and manage the facility.

Secretariat's approach to review and update the policy framework



Contents

- 1 NextGen Market Shaping – Results in GC7
- 2 Evolving NextGen Market Shaping for sustainable impact in GC8, supporting country transition
- 3 Spotlight: Accelerate and scale up the non-grant financed procurement mechanism
- 4 What is needed to ensure success**

What does success look like and how will progress be monitored?

GC8 strategic shifts are expected to:

- A** Faster and greater scaling up of more efficacious prevention, diagnosis and treatment tools across HIV, Tuberculosis and malaria, and mobilize additional resources to enable this
- B** Sustain markets, particularly for pediatric formulations and innovations; mitigate risks of supply disruptions and stock outs, while delivering on cost-efficiencies
- C** Increase procurement from regional manufacturers through procurement collaborations and capacity building partnerships.
- D** Drive strategic collaboration with countries to increase use of the non-grant financed procurement mechanism for health products where this adds value

Progress monitoring will be reported through:

- 1** Existing Strategic KPIs,
S8: On shelf availability
S9: Supply continuity
S10: Introduction of new products
- 2** Enhanced reporting through the annual Procurement and NextGen Market Shaping Update.
This includes additional information on:
 - i. Health product introductions
 - ii. Non-grant financed procurement
 - iii. Procurement through regional manufacturers

Leveraging the allocated NGMS CI funding across the strategic priorities will enable us to proceed with the evolved shifts for GC8

The planned investments aim to sustain the progress, to accelerate work on some interventions, and to catalyze additional partner contributions to generate greater impact.

STRATEGIC PRIORITIES	KEY INTERVENTIONS	Indicative allocation	FURTHER INVESTMENT OPPORTUNITIES
		US\$110m*	
1 Shape innovation and accelerate health product introduction at scale	<ul style="list-style-type: none"> • Access Fund • Revolving Facility First Loss Pool at current level • Country readiness support • Accelerated regulatory approvals – Expert Review Panel (ERP) 	US\$85m	<ul style="list-style-type: none"> • Access Fund: Additional funding required to expand Access Fund scope to further products and greater scale in more countries at a faster pace • Revolving Facility: Ability to respond to additional opportunities where this tool may accelerate the time to reduce pricing and greater supply of innovative health products • Country readiness: Greater support to enable timely adoption and scale up
2 Promote regional capacity building for manufacturing and collaborative procurement	<ul style="list-style-type: none"> • Pooled procurement capacity building and support for regionally diversified supply • Regulatory strengthening / harmonization 	US\$10m	<ul style="list-style-type: none"> • Pooled procurement: Deeper capacity building support to accelerate progress on regional pooled procurement efforts
3 Sustain healthy markets and drive integrated sustainable, efficient, resilient supply chains	<ul style="list-style-type: none"> • Market monitoring and early remedial interventions to address market failure • Develop sustainable supply chain financing models and approaches including links to health insurance benefits package designs • Develop alternative channels and integrated delivery models including last mile • Promote digital innovations for integrated demand planning and traceability 	US\$10m	<ul style="list-style-type: none"> • Ability to monitor and support healthy markets for downstream supply chain • Enable timely adoption and scaled adoption of innovative sustainable models • Integration in delivery models that allow for scaled uptake of key health products in a cost-efficient manner • Digital innovations: Limited introduction of traceability capability built for supply chain integrity monitoring
4 Accelerate scale-up of non-grant financed procurement	<ul style="list-style-type: none"> • Start-up and operationalizing scaled NGFP • Exploratory work on pre-financing facility 	US\$5m	<ul style="list-style-type: none"> • Establishing a pre-financing facility • Access financing to support scale up of innovative health products through non-grant channels

Market Shaping Strategic Priorities bring greater clarity to critical shifts and are fully aligned with Board-approved NextGen priority

To proceed with the evolved NGMS shifts, we intend to fully leverage the allocated CI funding across the strategic priorities

The proposed aims to sustain the progress, to accelerate work on some interventions, and to catalyze additional partner contributions to generate greater impact.

Priority	Components
NextGen Market Shaping & Response	Accelerate innovation and scaled use of products
	Promote sustainable regional manufacturing ecosystems
	Environmentally sustainable supply, delivery & distribution
Emergency Fund	
Address Human Rights & Gender Barriers	
Build Community Networks & Engagement	Community Networks & Engagement
Supporting Sustainability and Transition from Global Fund Financing	Responsible preparation for sustainability & transition
	Cross-border progress toward malaria elimination in Southern Africa
	Eliminating malaria in the Mekong region
Optimizing RSSH	Public Financial Management
	Reinforcing impact of focused, integrated RSSH-PPR investments
Climate and Health	Improved HTM outcomes through integration

STRATEGIC PRIORITIES	KEY INTERVENTIONS	Indicative allocation	FURTHER INVESTMENT OPPORTUNITIES
		US\$110m	
1 Shape innovation and accelerate health product introduction at scale	<ul style="list-style-type: none"> Access Fund Revolving Facility First Loss Pool at current level Country readiness support Accelerated regulatory approvals – Expert Review Panel (ERP) 	US\$85m	<ul style="list-style-type: none"> Access Fund: Additional funding required to expand Access Fund scope to further products and greater scale in more countries at a faster pace Revolving Facility: Ability to respond to additional opportunities where this tool may accelerate the time to reduce pricing and greater supply of innovative health products Country readiness: Greater support to enable timely adoption and scale up
2 Promote regional capacity building for manufacturing and collaborative procurement	<ul style="list-style-type: none"> Pooled procurement capacity building and support for regionally diversified supply Regulatory strengthening / harmonization 	US\$10m	<ul style="list-style-type: none"> Pooled procurement: Deeper capacity building support to accelerate progress on regional pooled procurement efforts
3 Sustain healthy markets and drive integrated sustainable, efficient, resilient supply chains	<ul style="list-style-type: none"> Market monitoring and early remedial interventions to address market failure Develop sustainable supply chain financing models and approaches including links to health insurance benefits package designs Develop alternative channels and integrated delivery models including last mile Promote digital innovations for integrated demand planning and traceability 	US\$10m	<ul style="list-style-type: none"> Ability to monitor and support healthy markets for downstream supply chain Enable timely adoption and scaled adoption of innovative sustainable models Integration in delivery models that allow for scaled uptake of key health products in a cost-efficient manner Digital innovations: Limited introduction of traceability capability built for supply chain integrity monitoring
4 Accelerate scale-up of non-grant financed procurement	<ul style="list-style-type: none"> Start-up and operationalizing scaled NGFP Exploratory work on pre-financing facility 	US\$5m	<ul style="list-style-type: none"> Establishing a pre-financing facility Access financing to support scale up of innovative health products through non-grant channels

The NextGen Market Shaping framework is organized around four (4) Strategic Priorities, which fall within the scope of the Board-approved NextGen CI priority

Next Steps

Board endorsement of these proposed shifts will enable moving forward with work planning, to be followed by further Committee and Board engagement

Board and Strategy Committee engagements

- **February 2026: B54**
 - Update on the work to review the policy framework for non-grant financed procurement, including an update on the development of a pre-financing facility.
 - Board decision on Sources and Uses of Funds for GC8, including NextGen Market Shaping CI amount that would sustain progress and accelerate prioritised interventions.
- **May 2026: SC30**
 - Annual update on NextGen Market Shaping and Procurement
 - Recommendation on the updated non-grant financed procurement mechanism, ahead of Board decision(s) if required.
- **July 2026: B55**
 - Decision(s) on the updated policy framework for the non-grant financed procurement mechanism, if a Board decision is required.

Input sought

Overall key questions for input

- 1 Does the updated NextGen Market Shaping approach appropriately respond to the evolving context, maximizing outcomes in GC8 and supporting country transitions, including the proposed acceleration and scaling up of the non-grant financed procurement mechanism as well as the development of a pre-financing facility?
- 2 Are the next steps, including Committee / Board engagement appropriate and on the right timeline?

Thank you



The Global Fund to Fight
AIDS, Tuberculosis and Malaria

+41 58 791 1700
theglobalfund.org

Annexes & Background Materials

The following items can be found in Annex:

Annex 1: Key Progress on NextGen Market Shaping in GC7

Annex 2: Relevant Past Board Decisions

Annex 3: Links to Relevant Past Documents & Reference Materials

Annex 1: Key Progress on NextGen Market Shaping in GC7

Accelerate Innovation and New Product Introduction [1/3]

DUAL ACTIVE INGREDIENT INSECTICIDE-TREATED NETS

Building on the foundation of the New Nets Project*, the Global Fund – in partnership with Gates Foundation – established its Revolving Facility in 2023 and used it to underwrite Volume Guarantees with Dual active ingredient (AI) suppliers. This achieved significant impact, including:

- ▶ **Accelerated transition:** More than two-thirds of GC7 demand shifted to Dual AI nets, an unprecedentedly rapid scale-up following the WHO recommendation in 2023. Dual AI nets are 45% more effective at preventing transmission in areas of pyrethroid-resistance.
- ▶ **Increased supply base for sustained market shift:** Achieved target of 5 prequalified suppliers of Dual AI insecticide-treated nets (ITNs), including suppliers with cutting and sewing capabilities in Africa.
- ▶ **Increased affordability:** Achieved prices close to parity with existing ITNs, reducing tradeoffs and enabling shift to more effective nets.



*The New Nets project was executed from 2019 – 2022 and included joint investments from the Global Fund and Unitaaid as well as collaboration with the Gates Foundation, MedAccess, IVCC, USG and other partners. It supported catalytic procurement, initial volume guarantees, and co-payments for Dual AI ITNs, achieving the evidence generation needed for the WHO recommendation in 2023.

Accelerate Innovation and New Product Introduction [2/3]

LENACAPAVIR FOR PrEP

Securing adequate capacity and access pricing with the originator manufacturer enabled simultaneous roll-out of Lenacapavir pre-exposure prophylaxis (LEN PrEP) in Global Fund-supported countries alongside high-income markets.

The early and scaled introduction also accelerated the development timelines for the generic products, supported by partners' efforts.

Through the Access Fund, the Global Fund enabled the mid-grant cycle introduction of LEN PrEP in nine countries—representing a transformational shift in HIV prevention for communities with the highest burden of new infections.

Partners' contribution to Access Fund removed financial barriers, accelerated country readiness, and ensured rapid deployment of this highly effective tool. First deliveries were achieved in record time following regulatory approval, with initial Lenacapavir volume delivered in Eswatini and Zambia in November 2025, subsequent deliveries expected from Q1 2026.



**Delivery of the first
Lenacapavir shipment to the
Central Medical Stores
facility in Eswatini,
November 2025**

Accelerate Innovation and New Product Introduction [3/3]

MULTIPLE FIRST LINE THERAPIES (MFTs) FOR MALARIA

To address rising antimalaria drug resistance, the Global Fund leveraged the Access Fund to procure alternative artemisinin combination therapies (ACTs) and advance MFT strategies. This initiative also stimulated market sustainability for current and future generics. Support to Burkina Faso, Ghana, Malawi, and Uganda delivered:




Savings: Over US\$2M in savings on ACT procurement for these countries, with additional savings for others adopting these products.



Diversification of first-line ACTs: to mitigate and preempt artemisinin resistance.

Status of Antimalaria Drug Resistance in Sub Saharan Africa



Powered by Bing
© GeoNames, Microsoft, OpenStreetMap, TomTom



AL = artemether/lumefantrine ASAQ = artesunate/amodiaquine
ASPY = artesunate/pyronaridine DP = dihydroartemisinin/piperaquine

Regional Capacity Building for Manufacturing and Procurement [1/3]

Procurement as a Driver of Regional Manufacturing

Through the Global Fund's Pooled Procurement Mechanism (PPM), US\$1.78 billion of health products were procured in 2024. PPM is governed by the QA policies that set out procurement eligibility criteria such as international quality standards and prequalification by stringent regulatory bodies - African manufacturers that meet these requirements are fully eligible to participate in our tenders.

The Global Fund's tenders support regional manufacturing by valuing offers from suppliers that produce closer to where health products are needed and total delivered costs. This approach enhances supply resilience and is reflected in our transparent and competitive assessment of bids.

In 2024, two Africa-based manufacturers in Kenya and Uganda delivered quality-assured HIV, TB and malaria medicines worth nearly US\$15 million through Global Fund procurement.

Catalyzing Regional Manufacturing Capacity


Through the NextGen Market Shaping Strategic Initiative, the Global Fund invests to strengthen Africa's capacity to manufacture and supply essential health products:

- 1 Working with WHO, the Global Fund supported training and technical assistance to African manufacturers and regulators on international quality, safety, and efficacy standards, including support for the Expert Review Panel (ERP) and WHO Prequalification submissions.
- 2 The Global Fund finances joint product assessments within Regional Economic Communities to advance regulatory harmonization and facilitate product registration across multiple countries.
- 3 To accelerate product access, Global Fund supported the Expert Review Panel mechanism for African-made HIV rapid tests and fund verification studies that help countries integrate new products into national HIV testing programs.
- 4 In partnership with the African Union, Africa CDC, SADC, EAC, and ECOWAS/WAHO, the Global Fund strengthens regional pooled procurement platforms to create predictable demand and sustain investment in African manufacturing.

In 2025, the Global Fund procured the **first African-made, WHO-prequalified HIV treatment** from Kenya for delivery to Mozambique, a milestone for regional manufacturing and supply security in Africa.

Regional Capacity Building for Manufacturing and Collaborative Procurement [2/3]

Partnering with regional procurement platforms to strengthen procurement capacity and efficient access - effective collaboration and coordination enables scale synergies and effective planning will support market stability and sustainable access to affordable and quality health products



Regional Capacity Building for Manufacturing and Collaborative Procurement [3/3]

Key progress on partnering with regional procurement platforms to strengthen country capacity and access includes:

Engagement and exploration

- 1 Ongoing dialogues with Africa CDC and Regional Economic Communities in Africa (SADC, EAC, ECOWAS/WAHO) on procurement collaboration and capacity building, aligned with Team Europe partners especially with GIZ in SADC.
- 2 Supported needs assessments and development of 5-year roadmaps to guide institutional capacity and procurement alignment with RECs and Africa CDC including collaboration with the Global Fund.

Proven partnership models

- 1 Collaboration with PAHO's Strategic Fund has enabled substantial quantities of ARVs procured through pooled arrangements using domestic financing.
- 2 Recently expanded PAHO MoU to enhance demand side collaboration including South-to-South procurement collaboration and capacity building in other regions.
- 3 Demonstrates how regional platform and PPM collaboration can be mutually beneficial to expand access, stabilize supply, and sustain affordability.
- 4 Lessons from PAHO are informing design discussions with African partners to adapt models for scale and sustainability.

Sustainable Supply Chain Management [1/1]

KEY ACHIEVEMENTS IN 2025

- 1 Catalytic investment in supply chains is complementing a total of ~US\$28M in grant system strengthening investments,¹ helping ensure efficient and timely implementation of larger country and partner programs.
- 2 Advanced supply chain sustainability by conducting cost-analysis and optimizing exercises to identify efficiency opportunities and develop comprehensive supply chain budgets and strategic plans.
- 3 Expanded access to quality-assured health products by designing alternative innovative and integrated delivery channels, primarily through private pharmacies and drug shops.
- 4 Shaped the Logistics marketplace including the development of a global logistics marketplace digital database to increase access to private sector providers.
- 5 In partnership with GFF, Gavi, Gates Foundation and World Bank, coordinated the 2025 Supply Chain Leaders Forum Conference, that led to the development of 25 country-led integration and sustainability plans, and a budgeting toolkit to guide national planning.
- 6 Catalyzed supply chain digitalization efforts including the development of digitalization standards, an effort to cover 100% of facilities in Gambia and fully digitalize Ethiopia's Pharmaceutical Supplies Agency.

**Catalytic Impact
Leveraged: US\$28M**

On-shelf availability (S8)²

% of health facilities with tracer health products available [on the day of visit] – Target 90%



HIV: 85%



TB: 80%



Malaria: 92%

Annex 2: Relevant Past Board Decisions

Relevant Past Decision Point	Summary and Impact
<u>GF/B52/DP06 Catalytic Investments for the 2026-2028 allocation period (Grant Cycle 8)</u> (November 2024)	Based on the recommendation of the Strategy Committee, the Board approved that the total amount of funding for catalytic investments in GC8 will be determined by the total amount of sources of funds for allocation for GC8. The Board also approved the catalytic priorities for GC8, based on the total amount of sources of funds for allocation. The decision included other aspects, including operational flexibilities for the Secretariat, including those which require reporting to the Strategy Committee and those which also require Strategy Committee approval.
<u>GF/B51/DP03 Quality Assurance Policy for Vector Control Products</u> (April 2024)	<p>Based on the recommendation of the Strategy Committee, the Board approved the Quality Assurance Policy for Vector Control Products and Related Equipment. It requested the Secretariat to work with the World Health Organization (WHO) to establish an Expert Review Panel for Vector Control Products and to conclude the necessary arrangements with WHO. It also delegated authority to the Secretariat, in consultation with the Strategy Committee Chair and Vice Chair, to make non-material adjustments to the Policy and to report back to the Strategy Committee and Board on all such changes.</p> <p>Additionally, while the Board expects efforts will be made to fully implement the Policy upon its approval, the Board noted that implementation of certain aspects of the Policy would require a reasonable transition period.</p>
<u>GF/B50/DP06 Amended and Restated Global Fund Quality Assurance Policy for Pharmaceutical Products and Amended and Restated Global Fund Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment</u> (November 2023)	<p>Based on the recommendation of the Strategy Committee, the Board approved:</p> <ol style="list-style-type: none">1. the Amended and Restated Quality Assurance Policy for Pharmaceutical Products; and2. the Amended and Restated Quality Assurance Policy for Medical Devices (including In-Vitro Diagnostics) and Core Personal Protective Equipment, which replaces in its entirety the former Quality Assurance Policy for Diagnostics Products. <p>The Board delegated authority to the Secretariat, in consultation with the Strategy Committee Chair and Vice Chair, to make non-material adjustments to these two quality assurance policies and to report back to the Strategy Committee and Board on all such changes.</p>
<u>GF/B48/DP07: Advancement of Non-Global Fund-Financed Procurement Utilizing the Pooled Procurement Mechanism and wambo.org</u> (November 2022)	Based on the recommendation of the Strategy Committee (GF/SC20/DP03), the Board approved the Secretariat's continued operationalization of the current scope of non-Global Fund-financed orders by governments and non-government development organizations in Global Fund-eligible countries, for products and services on wambo.org, removing any cap, with reporting on the non-Global Fund-financed procurement integrated into annual updates to the Board on NextGen Market Shaping implementation.

Annex 3: Links to Relevant Past Documents & Reference Materials

- a) Procurement and NextGen Market Shaping Update, GF/B53/05, (May 2025)
- b) Annex 5: 2026-2028 (Grant Cycle 8) Catalytic Investment Proposals Annex to GF/SC26/06E: Catalytic Investments for GC8, GF/SC26/06E, (October 2024)
- c) Quality Assurance Policy for Vector Control Products and Related Equipment, GF/B51/05 (April 2024)
- d) Global Fund Quality Assurance Policy Updates: Pharmaceutical Products and Medical Devices, including In-Vitro Diagnostics, and Core Personal Protective Equipment, GF/B50/05 (November 2023)
- e) Update on NextGen Market Shaping, GF/SC22/04 (July 2023)
- f) Drive equitable access to quality assured health products through NextGen Market Shaping, GF/B48/11 (November 2022)
- g) Non-Global Fund-financed procurement through wambo.org, GF/B48/05 (November 2022)
- h) Catalytic Investments for 2023-2025 Allocation Period: Frequently Asked Questions, GF/SC19/11C (July 2022)
- i) Supply Operations and Market Shaping Update, GF/SC17/19 (October 2021)